CORD-19:2008f024274c53b0de1276f4047a6a641813fd98 / 690085-690318 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/2008f024274c53b0de1276f4047a6a641813fd98","sourcedb":"CORD-19","sourceid":"2008f024274c53b0de1276f4047a6a641813fd98","text":"A decision analytic model was created to compare 2 strategies of 1st-, 2nd-and 3rd-line therapies: azithromycin/amoxicillin-clavulanate/levofloxacin (AZI/AMC/LEV), and telithromycin/amoxicillin-clavulanate/levofloxacin (TEL/AMC/LEV).","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"T25922","span":{"begin":0,"end":233},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T25922","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T116","span":{"begin":0,"end":233},"obj":"Sentence"}],"attributes":[{"subj":"T116","pred":"source","obj":"CORD-19_Custom_license_subset"}]},{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T6344","span":{"begin":26,"end":29},"obj":"Disease"},{"id":"T6345","span":{"begin":154,"end":157},"obj":"Disease"},{"id":"T6346","span":{"begin":224,"end":227},"obj":"Disease"}],"attributes":[{"id":"A6344","pred":"mondo_id","subj":"T6344","obj":"http://purl.obolibrary.org/obo/MONDO_0010518"},{"id":"A6345","pred":"mondo_id","subj":"T6345","obj":"http://purl.obolibrary.org/obo/MONDO_0015168"},{"id":"A6346","pred":"mondo_id","subj":"T6346","obj":"http://purl.obolibrary.org/obo/MONDO_0015168"},{"subj":"T6344","pred":"source","obj":"CORD-19-PD-MONDO"},{"subj":"T6345","pred":"source","obj":"CORD-19-PD-MONDO"},{"subj":"T6346","pred":"source","obj":"CORD-19-PD-MONDO"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#ecab93","default":true},{"id":"CORD-19_Custom_license_subset","color":"#9394ec"},{"id":"CORD-19-PD-MONDO","color":"#aeec93"}]}]}}